The multidisciplinary consortium of the PARADISE project, led by Professor Mark Little of Trinity College Dublin, consisting of experts from seven countries, integrating cutting-edge expertise in medicine, artificial intelligence, biomarker discovery, and ethics, met in person on 28-29 April 2025 in Freiburg, Germany. The meeting was hosted by project partner University of Freiburg.
The PARADISE project, funded by ERA PerMed has the ambitious goal to develop a deployable, personalised predictive tool that accurately assesses an individual’s immune system activation, focusing on ANCA vasculitis. By tailoring medication dosages—or safely discontinuing them altogether—PARADISE aims to redefine how autoimmune diseases are managed, significantly improving patient care and quality of life.
Over two sunny days in Freiburg, the consortium progressed key discussions about the patient data, samples and biomarkers that will inform the predictive tool being developed via complex statistical models. As the PARADISE predictive tool is driven by AI, a key focus of the meeting was how we ensure that the tool and the science behind it are both transparent and explainable, given the trust of clinicians that may use it and patients that can benefit from, are essential to the tool’s success. To aide these discussions, guest expert speakers shared the latest in relation to the AI Act and its practical implementation and three vasculitis patients were present to promote the patient perspective.
